Insider Transactions in Q4 2021 at Entasis Therapeutics Holdings Inc. (ETTX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 02
2021
|
Ruben Tommasi Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-5.37%
|
$7,338
$2.94 P/Share
|
|
Nov 02
2021
|
Michael Gutch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-7.93%
|
$7,338
$2.94 P/Share
|
|
Nov 02
2021
|
Manoussos Perros President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,704
-7.93%
|
$23,408
$2.94 P/Share
|
|
Nov 02
2021
|
John Patrick Mueller Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,907
-8.49%
|
$7,814
$2.94 P/Share
|
|
Nov 02
2021
|
David Altarac Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-7.93%
|
$7,338
$2.94 P/Share
|
|
Nov 02
2021
|
Elizabeth M Keiley General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-7.93%
|
$7,338
$2.94 P/Share
|
|
Nov 02
2021
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Payment of exercise price or tax liability
|
Direct |
3,669
-7.93%
|
$7,338
$2.94 P/Share
|
|
Oct 19
2021
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Open market or private sale
|
Direct |
3,759
-7.52%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
David Altarac Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,759
-7.52%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
David Altarac Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
Elizabeth M Keiley General Counsel |
SELL
Open market or private sale
|
Direct |
3,759
-7.52%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
Elizabeth M Keiley General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
Ruben Tommasi Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,759
-5.22%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
Ruben Tommasi Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+25.77%
|
-
|
|
Oct 19
2021
|
Michael Gutch Officer |
SELL
Open market or private sale
|
Direct |
3,759
-7.52%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
Michael Gutch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
John Patrick Mueller Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,001
-8.0%
|
$12,003
$3.19 P/Share
|
|
Oct 19
2021
|
John Patrick Mueller Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
Manoussos Perros President and CEO |
SELL
Open market or private sale
|
Direct |
11,974
-7.51%
|
$35,922
$3.19 P/Share
|
|
Oct 19
2021
|
Manoussos Perros President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
79,750
+33.33%
|
-
|